Positive top-line results for romosozumab FRAME study
UCB and Amgen have announced top-line results from the Phase III FRAME study romosozumab in postmenopausal women with osteoporosis. These data showed FRAME met the co-primary endpoints by reducing the incidence of new vertebral fracture through months 12 and 24 in postmenopausal women with osteoporosis treated with romosozumab.
Click on this link for more information.
